See the DrugPatentWatch profile for onivyde
No generic version of Onivyde is currently available [1].
When might a generic Onivyde become available?
The availability of a generic version of Onivyde depends on patent expirations and regulatory approvals. Drug patent information can be complex and is tracked by resources like DrugPatentWatch.com [2].
What is Onivyde used for?
Onivyde (irinotecan liposome injection) is a chemotherapy drug used to treat pancreatic cancer [3]. Specifically, it is indicated for patients with metastatic pancreatic adenocarcinoma whose disease has progressed following gemcitabine-based therapy [4].
How does Onivyde work?
Onivyde is a liposomal formulation of irinotecan, a topoisomerase I inhibitor. This means it works by interfering with a specific enzyme that cancer cells need to divide and grow [3]. The liposomal delivery system is designed to help irinotecan accumulate in tumor tissue and prolong its presence in the body [4].
What are the side effects of Onivyde?
Common side effects reported for Onivyde include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis (mouth sores), and fever [4]. Severe side effects can occur, and patients should discuss potential risks with their healthcare provider.
What is the difference between Onivyde and other irinotecan treatments?
Onivyde is a liposomal encapsulation of irinotecan. This formulation is distinct from other forms of irinotecan, such as the non-liposomal irinotecan hydrochloride injection, which may have different dosing, administration, and side effect profiles [3][4]. The liposomal form is intended to alter the drug's pharmacokinetic properties, potentially affecting how it is absorbed, distributed, metabolized, and excreted.
Who manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals [3].
What are the patent considerations for Onivyde?
The patent status of Onivyde, like other branded drugs, plays a crucial role in determining when generic competition can emerge. Patent expiry dates dictate the period of market exclusivity for the innovator drug. Information on drug patents and their expiration can be found through specialized databases [2].
What are the risks of developing a generic for Onivyde?
Developing a generic drug involves proving bioequivalence to the branded drug and obtaining regulatory approval, which can be a complex and costly process. The patent landscape surrounding Onivyde would be a primary consideration for any company looking to develop a generic version.
Are there alternative treatments for pancreatic cancer?
Several other treatment options exist for pancreatic cancer, depending on the stage and type of cancer, as well as the patient's overall health. These may include other chemotherapy regimens, radiation therapy, surgery, and targeted therapies [5].
How is Onivyde administered?
Onivyde is administered intravenously, meaning it is given through an IV infusion [4].
What is the clinical data supporting Onivyde?
The efficacy and safety of Onivyde were evaluated in clinical trials. For example, a Phase 3 study called the NAPOLI-1 trial demonstrated a survival benefit for patients treated with Onivyde in combination with 5-fluorouracil and leucovorin compared to those receiving those agents alone or Onivyde alone [4].
How is Onivyde regulated?
Onivyde is approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) for its indicated use in treating pancreatic cancer [3].
Can biosimilars be made for Onivyde?
Onivyde is a small molecule drug, not a biologic. Therefore, the concept of biosimilars, which applies to biologic drugs, does not apply here. Generic versions are the relevant form of post-patent competition for small molecule drugs like Onivyde.
What is the cost of Onivyde?
The cost of Onivyde can vary and is subject to factors such as insurance coverage, pharmacy pricing, and potential patient assistance programs. It is a branded chemotherapy agent, which typically carries a significant price tag [4].
---
Sources:
[1] https://www.drugs.com/availability/generic-onivyde.html
[2] https://drugpatentwatch.com/
[3] https://www.onivyde.com/
[4] https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206050s000lbl.pdf
[5] https://www.cancer.org/cancer/types/pancreatic-cancer/treatment.html